Institutional shares held 322 Million
378K calls
575K puts
Total value of holdings $2.01B
$2.35M calls
$3.58M puts
Market Cap $1.74B
280,497,984 Shares Out.
Institutional ownership 114.94%
# of Institutions 312


Latest Institutional Activity in FOLD

Top Purchases

Q2 2025
Assenagon Asset Management S.A. Shares Held: 3.53M ($22M)
Q2 2025
Tempus Wealth Planning, LLC Shares Held: 53.1K ($330K)
Q2 2025
111 Capital Shares Held: 13.4K ($83.1K)
Q2 2025
Klp Kapitalforvaltning As Shares Held: 49.6K ($309K)
Q2 2025
Parallel Advisors, LLC Shares Held: 4.11K ($25.5K)

Top Sells

Q2 2025
Truist Financial Corp Shares Held: 22.5K ($140K)
Q2 2025
Gsa Capital Partners LLP Shares Held: 57.2K ($356K)
Q2 2025
Gamma Investing LLC Shares Held: 20 ($124)
Q2 2025
Massmutual Trust CO Fsb Shares Held: 228 ($1.42K)
Q2 2025
Farther Finance Advisors, LLC Shares Held: 32 ($199)

About FOLD

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.


Insider Transactions at FOLD

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.19M Shares
From 15 Insiders
Grant, award, or other acquisition 1.15M shares
Exercise of conversion of derivative security 45.8K shares
Sell / Disposition
387K Shares
From 7 Insiders
Payment of exercise price or tax liability 342K shares
Open market or private sale 45.8K shares

Track Institutional and Insider Activities on FOLD

Follow AMICUS THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells FOLD shares.

Notify only if

Insider Trading

Get notified when an Amicus Therapeutics, Inc. insider buys or sells FOLD shares.

Notify only if

News

Receive news related to AMICUS THERAPEUTICS, INC.

Track Activities on FOLD